الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
The aim of the present work was to study the impact and outcome of amyloidosis on long term kidney transplantation. Twenty three kidney transplant recipients with amyloidosis were included in the study. Amyloidosis was diagnosed by renal biopsy. Out of twenty three amyloidotic recipients, 16 had amyloidosis secondry to familial Mediterranean fever, while in the rest, amyloidosis was primary as no evidence of proceeding or co-existing diseases were detected in them. All the amyloidotic recipients were given oral colchicine (I, 2gm/day) once the diagnosis of amyloidosis was established and maintained on it.indefinitly, A control group of 47 renal allograft recipients in whom end-stage renal failure was secondry to other aetiologies was selected randomly from the transplant registry field by date of operation. The two groups were comparable with respect to age, sex, duration of transplantation and the immunosuppressive regimens used. The donors in both groups were homogenous regarding age, sex and the degree of HLA matching. The two groups of recipients were compared as regarding serum creatinine concentration, ciclosporine dose, frequency and time of occurance of rejection episodes, blood pressure values and the development of significant gastrointestinal manifestations. Also, the neuromuscular status was evaluated in both groups through complete neurological examination, estimation of serum levels of muscle enzymes, electromyography and nerve conduction velocity. Our results showed no significant differences between the two groups regarding serum creatinine concentrations and ciclosporine doses when studied at comparable time points. However, the amyloidotic recipients had less frequencies of post transplant rejection episodes